Abstract
Twenty-five women using levonorgestrel containing the contraceptive implant, NorplantR-2 were studied longitudinally, to see the effects on lipid profile, glucose tolerance and hepatic transaminases with short-term (12 weeks) and long-term (18 to 24 months) use of Norplant-2. Total lipids, cholesterol, phospholipids, triglycerides and their subfractions were evaluated. There was a significant increase in LDL-cholesterol after 12 weeks of use (p<0.05), which did not persist at 18–24 months follow-up. The HDL-cholesterol, HDL/LDL-cholesterol ratio, phospholipids, other lipid fractions, hepatic transaminases and glucose tolerance did not alter significantly following short-term or long-term use of Norplant-2.
Resumé
Vingt-cinq femmes utilisant un contraceptif contenant du lévonorgestrel, le Norplant-2, ont fait l'objet d'une étude longitudinale visant à déceler les effects de l'utilisation de ce contraceptif sur le profil des lipides, la tolérance au glucose et les transaminases hépatiques, à court terme (12 semaines) et à long terme (18 à 24 mois). On a évalué les lipides totaux, le cholestérol, les phospholipides, les triglycérides et leurs sous-fractions. On a constaté une augmentation significative du LDL cholestérol après 12 semaines d'utilisation (p<0,05), qui n'existait plus lors des visites de suivi 18 et 24 mois plus tard. Le HDL cholestérol, le rapport entre les HDL et LDL cholestérol, les phospholipides, les autres fractions lipidiques, les transaminases hépatiques et la tolérance au glucose n'ont pas été significativement modifiés par l'utilisation à court ou à long terme du Norplant-2.
Resumen
Veinticinco mujeres que utilizaban un anticonceptivo que contenía levonorgestrel, el Norplant-2, fuerón objeto de un estudio longitudinal a los efectos de determinar el perfil de lípidos, la tolerancia a la glucosa y las transaminasas hepáticas en el uso a corto plazo (12 semanas) y a largo plazo (18 a 24 meses). Se evaluaron los lípidos totales, el colesterol, los fosfolípidos, los triglicéridos y sus subfracciones. Se verificó un aumento significativo de LDL colesterol tras 12 semanas de utilización (p<0,05), que no persistió en las visitas al cabo de 18 y 24 meses de utilización. El HDL colesterol, la relación entre los HDL y LDL colesterol, los fosfolípidos, las otras fracciones de lípidos, las transaminasas hepáticas y la tolerancia a la glucosa no fueron modificados significativamente por la utilización a corto o a largo plazo del Norplant-2.
Similar content being viewed by others
References
FotherbyK. (1989). Oral contraceptives and lipids.Br. Med. J.,298, 1049–1059
MannJ.I. (1982). Progestogens in cardiovascular disease—introduction on epidemiological data.Am. J. Obstet. Gynecol.,142, 752–754
OsterP., ArabD., KohlmeierM., MordasiniR., SchellenvergB. and SchlierfG. (1982). Effects of estrogens and progestogens on lipid metabolism.Am. J. Obstet. Gynecol.,142, 773–775
BriggsM.H. and BriggsM. (1981). A randomised study of metabolic effects of four low-estrogen oral contraceptives. Results after six cycles.Contraception,23, 463
WynnV. and NiththyannanthanR. (1982). The effect of progestin in combination oral contraceptives on serum lipids.Am. J. Obstet. Gynecol.,142, 766–782
DiazS., PavejM., RobertsonD.N. and CroxattoH.B. (1977). Clinical trials with subdermal implants of progestin R-2323.Contraception,16, 155–165
DiazS., CroxattoH.B. and PavejM. (1985). Clinical chemistry in women treated with six levonorgestrel covered rods or with copper intrauterine device.Contraception,31, 321–331
ShaabanM.M., ElwanS.I., AbdallaS.A. and DarwishH.A. (1984) Effects of subdermal levonorgestrel implant — Norplant on serum lipids.Contraception,30, 413–419
Indian Council of Medical Research Task Force on Hormonal Contraception (1988). Phase-III clinical trials with Norplant-2 (covered rods) report of a 24 months study.Contraception,38, 659–674
HatchF. and LeesR.S. (1968). Practical methods for plasma lipoprotein analysis. In:Advances in Lipid Research, Vol. 6, R.Paolette and D.Kritchersky, eds, Academic Press, New York, pp. 1–68
FringsC.S. and DunnR.T. (1970) A colorimetric method for determination of total serum lipids based on the sulfo-phospho-vanillin reaction.Am. J. Clin. Pathol.,53, 89–90
ZakS. (1957). Simple and rapid microtechnique for serum cholesterol.Am. J. Clin Pathol.,27, 583–586
VanHandelE. and ZilversmitB.B. (1957). Micromethod for the direct determination of serum triglycerides.J. Lab. Clin. Med.,50, 152–154
BartlettG.R. (1959). Phosphorus assay in column chromotography.J. Biol. Chem.,234, 466
World Health Organization Task Force on Oral Contraceptives (1985). A randomised double blind study of the effects of two low-dose combined oral contraceptives on biochemical aspects.Contraception,32, 223–236
KayC.R. (1982). Progestogens and arterial diseases.Am. J. Obstet. Gynecol.,142, 762–765
BradleyD.D., WingerdJ., PattitiD.B., KraussR.M. and RamcharanS. (1978). Serum high density lipoprotein cholesterol in women using oral contraceptives — estrogens and progestins.N. Engl. J. Med.,299, 17–19
DashD.S., DasS., NandaU., TripathyB.B. and SamalK.C. (1988). Serum lipid profile in women using levonorgestrel, contraceptive implant, Norplant.Contraception,37, 371–382
SinghK., ViegasO.A.C., KohS., SinghP. and RatnamS.S. (1989). Two year follow-up of clinical chemistry in Singaporean Norplant-2 rod acceptors: metabolic changes.Contraception,39, 147–154
RoyS., MishellD.R., RobertsonD.N., RonaldN., KraussM., LacareaM. and DudaM.J. (1984). Long-term reversible contraception with levonorgestrel-releasing Silastic rods.Am. J. Obstet. Gynecol.,148, 1006–1012
AffandiB., SuhermanS.K., PrihartonoD.J., LubisF. and SamilR.S. (1987). Serum lipids in Norplant implant users.Contraception,36, 429–435
DiazS., PavejM., RobertsonD.N. and CroxattoH.B. (1979). A three year clinical trial with levonorgestrel Silastic implants.Contraception,19, 557–576
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Bala, Y., Dhall, G.I. & Majumdar, S. Short-term and long-term effects of NorplantR-2 on plasma lipoproteins and glucose tolerance. Adv Contracept 7, 77–83 (1991). https://doi.org/10.1007/BF01850721
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01850721